LP2, the first lanthipeptide GPCR agonist in a human pharmacokinetics and safety study

• Published in: Peptides (New York, N.Y. : 1980) Vol. 136; p. 170468
• Main Authors: Namsolleck, Pawel, Richardson, Alan, Moll, Gert N., Mescheder, Axel
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 01.02.2021
• Subjects: agonists; aminopeptidases; Angiotensin; dogs; genotoxicity; GPCR; humans; Lanthionine; males; Peptidase-resistance; pharmacokinetics; placebos; proteolysis; RAS; rats; subcutaneous injection; urine; Lanthionine; Peptidase-resistance; GPCR; RAS; Angiotensin
• ISSN: 0196-9781; 1873-5169; 1873-5169
• DOI: 10.1016/j.peptides.2020.170468

•Lanthipeptide LP2 is safe in a human SAD study.•LP2 has a T½ of approximately 2.1–2.6 h.•LP2 is largely recovered intact in urine. Introduction of a lanthionine into a peptide may enhance target affinity, target specificity and proteolytic resistance. This manuscript reports preclinical safety studies and the first-in-human study with the lanthipeptide AT2R agonist LP2, a structural analog of cAng-(1–7), whose N-terminus was protected against aminopeptidases by the presence of a d-lysine. None of the preclinical studies, including an in vitro multitarget panel, behavioral, respiratory and cardiovascular measurements, genotoxicity and toxicity studies in rat and dog, posed any safety concern. Due to lack of toxicity the maximum tolerated dose was not reached neither in rat nor in dog. In the human dose escalation study, healthy male volunteers received a single 1 mL subcutaneous injection (0.001 mg, 0.01 mg or 0.1 mg) of LP2 or matching placebo. In contrast to angiotensin II which has a T1/2 in plasma of < 1 min, LP2 has a T1/2 of approximately 2.1–2.6 hours. The fraction of the dose excreted unchanged in urine ranged from 84.73 ± 10.4 % at a dose of 0.001 mg to 66.4 ± 3.9 % at 0.1 mg. There were no deaths, serious adverse events or subject withdrawals as a result of an adverse event. The incidence of adverse events was 16.7 %; each was mild in severity. One adverse event, peripheral coldness, was considered to be possibly related to LP2 at 0.001 mg LP2. None of the results was considered to pose a clinically relevant safety concern. This study supports the potential for the therapeutic use of lanthipeptides.